SHANGHAI – Hutchison Medipharma Ltd., a Shanghai-based drug R&D subsidiary of Hutchison China Meditech, with its partner Astrazeneca plc, enrolled 90 patients at 22 sites in a global phase II trial for savolitinib (AZD6094) in papillary renal cell carcinoma (PRCC), a type of cancer that afflicts 48,000 people annually, or about 14 percent of new cases of kidney cancer in the world.